Updated:
Codexis
Codexis is an enzyme engineering company led by Stephen Dilly that supplies proprietary enzymes for more approved drugs than any competing platform.
Codexis
Codexis was founded in 2002 and is headquartered in Redwood City, California. The firm has built its business around enzyme optimization, using its CodeEvolver technology platform to design custom enzymes for pharmaceutical and diagnostic applications. The company's primary focus areas are RNA manufacturing, pharma biocatalysis, and molecular biology diagnostics. Its ECO Synthesis manufacturing platform enables enzymatic production of siRNA therapies, replacing traditional chemistry with cleaner, scalable processes. In 2022, Codexis launched its RNA Therapeutics Program, and by 2023-2025 it expanded into RNA and diagnostic markets. The company also serves pharmaceutical partners with biocatalytic solutions for small molecule API synthesis. Its geographic footprint is primarily North America, with a service reach extending globally through partner contracts. Codexis is publicly traded (NASDAQ: CDXS) and reported a market capitalization of approximately $200 million as of early 2026. The firm employs over 200 people, including a leadership team led by Executive Chairman Stephen Dilly (formerly CEO from August 2022 to November 2025) and CFO/Chief Business Officer Georgia Erbez (joined September 2024). In 2025, Codexis launched the ECO Innovation Lab to accelerate RNA manufacturing technology (per the firm, 2025). The company maintains no disclosed philanthropic structures. A structural differentiator is Codexis's dual role as both a product company selling enzymes and a service provider engineering custom biocatalytic solutions. This hybrid model, combining deep enzymology with machine learning via CodeEvolver, creates high barriers to replication and a recurring revenue stream from both product sales and licensing deals.
General information
Firm type
other
Year founded
2002
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Redwood City
Corporate office
Redwood City, CA, United States
Principals
Stephen Dilly
Executive Chairman
Georgia Erbez
Chief Financial Officer and Chief Business Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Codexis?
Stephen Dilly serves as Executive Chairman, overseeing strategic direction. Georgia Erbez is CFO and Chief Business Officer, managing financial operations and business development.
Is Codexis structured as a family office or a publicly traded company?
Codexis is a publicly traded enzyme engineering company (NASDAQ: CDXS). It is not a family office.
What investment stages does Codexis target?
Codexis does not make investments. It provides enzyme engineering and manufacturing services to pharmaceutical, biotech, and diagnostic clients across R&D and commercial stages.
Which sectors does Codexis explicitly avoid?
The firm does not publicly disclose exclusions beyond its stated focus on RNA manufacturing, pharma biocatalysis, and diagnostics. It does not operate in consumer goods or agricultural enzyme markets.
How does Codexis source proprietary deal flow?
Codexis originates business through direct partnerships with pharmaceutical and biotech companies seeking enzyme engineering for drug manufacturing and diagnostics. The firm also engages with academic institutions and research organizations.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: